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Despite substantial progress in electrotherapy, 
sustained ventricular tachycardia (VT) and elec-
trical storm remain the frequent causes of death 
among patients with end-stage heart failure (HF). 
A radiofrequency (RF) ablation (RFA) is a well-
recognized treatment option for patients with 
electrical storm who suffer from resistant VT [1].
Recently we published the clinical and hemo-
dynamic results of a 66-year-old patient with HF, 
left ventricular ejection fraction 20%, who under-
went a novel therapy based on atrial septostomy 
followed by implantation of the Atrial Flow Regu-
lator (AFR, Occlutech, Helsingborg, Sweden) [2]. 
Six weeks after AFR implantation, the patient was 
hospitalized because of recurrent VT with multiple 
appropriate cardioverter-defibrillator (ICD) shocks. 
On admission, the patient was conscious and hemo-
dynamically stable. He was taking beta-blocker 
and amiodarone for an extended period before 
recent hospitalization. During the patient’s stay 
in the intensive care unit, a basic pacing rhythm 
was increased to 100/min, and continuous infusion 
of lignocaine up to 120 mg per hour was started. 
The patient received sedation, however, sustained 
VT recurred during the following couple of days. 
Therefore, a decision was made to perform an 
electrophysiological study followed by RFA.
The procedure was done on 4th of March 2020.
Under local anesthesia and sedation with 
remifentanil and midazolam, right femoral vein ac-
cess was obtained. A 0.032 guidewire was placed into 
the left atrium through the 8 mm fenestration in the 
AFR device in the first step. Steerable sheath (Agilis 
NxT large curve) was introduced into the left atrium 
using the 8 mm hole (Fig. 1). The procedure was per-
formed using the Ensite Precision three-dimensional 
mapping system (Abbott Cardiovascular). Substrate 
mapping and ablation of conductive channels within 
the scar approach was planned. During right ventricle 
pacing from implanted ICD, a potential bipolar map 
was obtained with an HDGrid catheter. An extensive 
scar of the anterior wall, including the anterior part 
of the septum and apex, was mapped. Also, low and 
late potentials were found, especially in the apex and 
mid anterior wall (Fig. 1). During catheter manipula-
tion, clinical arrhythmia was easily induced. Because 
of acceptable tolerance,  an activation map during 
VT was also obtained, revealing the exit of the VT 
loop in the mid-region of the anterior wall. Pacing 
within the scar of this site resulted in S-QRS 150 ms 
with 90% QRS morphology concordance. HDGrid 
mapping catheter was exchanged to TactiCath SE 
F-J ablation catheter, and RF applications in this 
region (50 W 30 s) was applied. Rapid ventricular 
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stimulation-induced another VT with a loop exit-
ing scar in the apical region. RF applications (55 W 
30 s) resulted in the abolition of late potentials 
in this area and the arrhythmia’s non-inducibility.
The patient was discharged home on the 
third day after the procedure. He remained free of 
ventricular arrhythmia during 3 months follow-up.
The AFR is a self-expandable double-disc 
nitinol wire mesh construction allowing commu-
nication across the interatrial septum through an 
8 mm fenestration. This communication enables 
the decompression of the left atrium and may 
improve patients’ symptoms [3].
We have successfully implanted ten AFR de-
vices thus far in patients with severe HF. These 
procedures were done as part of an ongoing PRO-
LONGER trial (Pomeranian atRial flOw reguLatOr 
iN conGestive hEart failuRe; No. NCT04334694 at 
clinicaltrials.gov). According to available research, 
this is the first published data on performing an 
RFA in a patient with an electrical storm using 
a fenestration in AFR.
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Figure 1. A. Left anterior oblique 30 view of the steerable sheath with the ablation electrode introduced through Atrial 
Flow Regulator device; B. Bipolar map of the extensive anterior wall, septum, and apical scar with patchy areas in 
apex and late potentials recorded in this region; C. Long S-QRS interval during anterior part of septum stimulation 
(capture of conducting channel in a scar) with similar to ventricular tachycardia paced QRS morphology. 
